Working… Menu
Trial record 1 of 1 for:    OVAR17
Previous Study | Return to List | Next Study

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01462890
Recruitment Status : Active, not recruiting
First Posted : November 1, 2011
Last Update Posted : January 13, 2021
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Information provided by (Responsible Party):
AGO Study Group

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 2021